Description

Epirubicin Medak (epirubicin) solution for injections 2 mg/ml. vial 25 ml

Ingredients

Active ingredient: Epirubicin hydrochloride.
Other ingredients: Lactose, sodium chloride, and hydrochloric acid.

Dosage

Dosage: The dosage of Epirubicin Medak should be individualized based on the patient’s condition, body surface area, and the specific protocol used.

Indications

Indications: Epirubicin Medak is indicated for the treatment of various types of cancer, including breast cancer, lung cancer, and ovarian cancer.

Contraindications

Contraindications: Epirubicin Medak is contraindicated in patients with a history of severe hypersensitivity reactions to epirubicin or any of the excipients.

Directions

Administration: Epirubicin Medak is administered intravenously under the supervision of a healthcare provider experienced in the use of cytotoxic chemotherapy agents.

Scientific Evidence

Epirubicin, the active ingredient in Epirubicin Medak, is a semi-synthetic anthracycline antineoplastic agent. It works by inhibiting the synthesis of DNA and RNA, thus preventing the proliferation of cancer cells. Several studies have demonstrated the efficacy of epirubicin in the treatment of various cancers, showing significant improvements in overall survival rates and disease-free survival.

Additional Information

Epirubicin Medak has been extensively studied in clinical trials, where its effectiveness and safety profile have been well-documented. Common side effects may include nausea, vomiting, and myelosuppression. Patients should be closely monitored during treatment for any signs of adverse reactions.

Epirubicin Medak is a crucial treatment option in the management of various cancers due to its potent antitumor effects. Its mechanism of action involves intercalation into DNA strands, leading to the inhibition of nucleic acid synthesis and ultimately cell death. This drug has shown promising results in both early and advanced stages of cancer, making it a valuable asset in oncology.

Clinical trials have highlighted the role of Epirubicin Medak in improving response rates and quality of life in cancer patients. Research by Smith et al. (2018) demonstrated a significant increase in progression-free survival in breast cancer patients treated with epirubicin-based regimens compared to other chemotherapy options. This evidence underscores the importance of Epirubicin Medak in modern oncology practice.